Corcept ‘disappointed’ in court ruling over Teva patent dispute

Corcept Therapeutics Incorporated (CORT) announced that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ (TEVA) marketing of a generic version of Korlym does not infringe two of Corcept’s patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme, including drugs that are commonly prescribed to patients with Cushing’s syndrome. The ruling affirms a December 2023 verdict by the Federal District Court for the District of New Jersey. “We are disappointed in the Court’s ruling,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “The patents we asserted in this case cover methods of safely treating patients with Cushing’s syndrome that physicians rely on every day. We will vigorously defend our rights and are currently considering the best way to pursue judicial review of this decision.”